XinQing Medical Named One of CCI's Top 10 Innovative Enterprises for Pioneering Domestic Breakthroughs in Advanced Life Support Devices

Recently, the 10th anniversary celebration of the China Cardiovascular Innovators Club (CCI) was held in grand fashion. This event brought together top innovative forces in the cardiovascular field.Professor Ge Junbo, Academician of the Chinese Academy of Sciences, Director of the Cardiology Department at Zhongshan Hospital Affiliated to Fudan University, and President of the China Cardiovascular Innovation Club (CCI Innovation Academy), personally presented the award to magAssist.—— With continuous technological breakthroughs and key clinical outcomes in the field of mechanical circulatory support, magAssist has successfully won the 「Top Ten Innovative Enterprises"Honor."

At the same time, magAssist has gained significant recognition from both government and industry, forming a dual certification pattern of "industry + provincial/municipal government": its self-developed fully magnetically levitated artificial heart, MoyoAssist®, has not only been selected for inclusion in "Top Ten Industrial Scientific and Technological Achievements in Suzhou 2025"，recognized as a municipal industrial innovation benchmark; and even won the " assessment by the Jiangsu Provincial Association for Science and Technology.Top Ten Scientific and Technological Advances in Jiangsu Province's Industry Fields (Biomedical Field)", becoming a leading representative in the technical field of provincial细分 industries.

The dual endorsement formed by industry benchmark certification and provincial government recognition not only represents a high level of approval for magAssist's robust R&D capabilities and outstanding clinical value but also serves as profound evidence of its unwavering commitment to the innovation principle of "patient-centeredness." From technological breakthroughs to clinical implementation, magAssist’s innovative practices have consistently revolved around patient needs. These two honors are authoritative affirmations of its past achievements and further highlight its leading role in innovation within the mechanical circulatory support field.

1. Key to Winning: Dual-Core Products Break Through Technical Barriers

The core of magAssist's award-winning achievements lies in the breakthrough progress of two products: one is the NyokAssist® Interventional Artificial Heart, which received the "Breakthrough Device" designation from the U.S. FDA in August 2023, becoming the first interventional artificial heart in China to receive this certification. It also simultaneously obtained the "Innovative Medical Device" certification from China's NMPA, achieving "dual innovation in China and the U.S." and filling the gap in minimally invasive interventional life support devices in China; the other is the MoyoAssist® Fully Magnetically Levitated Artificial Heart, which received NMPA marketing approval in April 2024 and is the first extracorporeal ventricular assist system in China to adopt fully magnetic levitation technology.

Since its establishment in 2017, magAssist has been committed to the concept of "Technology Moves Life," building a full-cycle heart failure treatment product portfolio. The company has submitted over 300 patent applications, solidifying its technological moat.

2. Product Innovation: Addressing Clinical Pain Points

• NyokAssist®：As the world's smallest minimally invasive interventional artificial heart, with a 9Fr (approximately 3mm) ultra-fine size, it reduces vascular trauma by 40% compared to traditional products. Once inside the body, it quickly expands to a 21Fr operational size, achieving high flow output at low rotational speeds while reducing the risk of blood cell damage. The external motor design effectively avoids hemolysis caused by heat generation inside the body, significantly improving blood compatibility.

• MoyoAssist®：Adopting globally advanced computational fluid dynamics technology, it achieves 30 days of continuous support, with blood compatibility reaching an internationally leading level. In collaboration with Wuhan Union Hospital, it realizes China's first minimally invasive implantation surgery, reducing patient trauma.

• Multi-Organ Support Platform：New Generation ECMO Shared Control Platform Enhances Collaboration; Warm Blood Organ Transport Platform Achieves Stable Heartbeat of Ex Vivo Heart for Over 13 Hours, Breaking Through Traditional Cold Ischemia Protection Limitations.

3. Industry Value: Breaking Monopolies, Benefiting People's Livelihood

Product Breaks Monopoly of International Giants like Medtronic and Abbott, External Magnetic Levitation Artificial Heart Priced at Only 60% of Imported Products; Clinical Data Shows 40% Increase in Acute Heart Failure Rescue Success Rate, 50% Reduction in Complication Rate, and Expands Treatment Possibilities for Elderly Patients with Poor Vascular Conditions.

The company is deeply involved in "industry-university-research-application," collaborating with 12 clinical centers to promote the formulation of industry standards. It has been selected as a "potential unicorn enterprise" in Jiangsu Province for four consecutive years and won the German iF Design Award.

4. Future Planning: Expanding Globally, Researching Multiple Organs

In the future, magAssist will advance the NyokAssist® clinical trials in Europe and the United States, aiming to obtain CE certification by 2026. It will also develop multi-organ support devices for the lungs, kidneys, and more, while integrating AI technology to create intelligent life-support systems. As a leading enterprise in the Suzhou New District's medical device industry cluster, magAssist’s growth reflects the evolution of China’s high-end medical devices from "catching up" to "running alongside" and "leading the way." This award not only affirms its achievements but also highlights the independent innovation capabilities of China's medical technology.

- END -